Metabolic Health
FDA Approves Utebzi for Complicated Urinary Tract Infections Including Pyelonephritis
Tebipenem pivoxil becomes the first oral carbapenem approved in the US, offering a non-IV option for serious UTIs.
Drug Approval
Jun 21, 2026 0
Results for "Hyperbaric Oxygen Therapy"
20 articles
Cancer Research
FDA Approves Zenocutuzumab-zbco for Advanced Cholangiocarcinoma
The FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma, a rare and aggressive bile duct cancer with limited treatment options.
Drug Approval
May 13, 2026 0
Cancer Research
FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant Lung Cancer
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
Drug Approval
Apr 21, 2026 0
Cancer Research
FDA Greenlights Two New HER2-Targeted Lung Cancer Drugs in Recent Months
Zongertinib and sevabertinib earn FDA accelerated approvals for HER2-mutant NSCLC, expanding targeted therapy options for a historically hard-to-treat subset.
Drug Approval
Apr 28, 2026 0
Cancer Research
FDA Approves Two New HER2-Targeted Lung Cancer Drugs in 2025
Sevabertinib and zongertinib win FDA approval for HER2-mutant NSCLC, expanding targeted therapy options for previously treated patients.
Drug Approval
May 24, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutant Lung Cancer in Landmark Targeted Therapy Win
Zongertinib (Hernexeos) wins accelerated FDA approval for metastatic NSCLC with HER2 tyrosine kinase domain mutations, filling a critical treatment gap.
Drug Approval
Apr 20, 2026 0
Metabolic Health
FDA Approves Baxfendy, a New Aldosterone Synthase Inhibitor for Hypertension
Baxdrostat becomes the first-in-class aldosterone synthase inhibitor approved to treat resistant hypertension alongside existing drugs.
Drug Approval
May 19, 2026 0
Cancer Research
FDA Grants Expanded Approval to Zongertinib for HER2-Mutant Lung Cancer
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Drug Approval
May 6, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutated Lung Cancer in February 2026
New targeted therapy offers hope for patients with specific genetic mutations in non-small cell lung cancer.
Drug Approval
Apr 15, 2026 0
Cancer Research
FDA Approves Keytruda Combo for Platinum-Resistant Ovarian Cancer
Pembrolizumab plus chemotherapy gains FDA approval for PD-L1-positive ovarian cancer patients who failed prior treatment.
Drug Approval
Apr 20, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutant Non-Small Cell Lung Cancer
Zongertinib (Hernexeos) wins FDA approval for unresectable or metastatic HER2-mutant non-squamous NSCLC, expanding targeted therapy options.
Drug Approval
May 1, 2026 0
Cancer Research
FDA Approves Sonrotoclax for Hard-to-Treat Mantle Cell Lymphoma
Sonrotoclax (Beqalzi), a next-gen BCL-2 inhibitor, wins accelerated FDA approval for relapsed or refractory MCL after BTK inhibitor failure.
Drug Approval
May 15, 2026 0
Brain Health
FDA Approves First Drug to Treat Neurologic Complications of Hunter Syndrome
Avlayah (tividenofusp alfa-eknm) becomes the first therapy approved to address brain damage in Hunter syndrome, a rare pediatric disorder.
Drug Approval
Apr 28, 2026 0
Metabolic Health
FDA Approves Two New Weight Loss Drugs Foundayo and Zepbound for Obesity
FDA approves Foundayo (orforglipron) and Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight conditions.
Drug Approval
Apr 4, 2026 0
Heart Health
FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy
Myqorzo (aficamten) wins FDA approval for symptomatic obstructive HCM, offering a novel cardiac myosin inhibitor option for patients.
Drug Approval
Jun 14, 2026 0
Cancer Research
FDA Approves Nivolumab Combo for Classical Hodgkin Lymphoma
Nivolumab added to standard chemotherapy wins FDA approval, offering a new frontline option for classical Hodgkin lymphoma patients.
Drug Approval
May 26, 2026 0
Cancer Research
FDA Approves Nivolumab Combination Regimen for Classical Hodgkin Lymphoma
Nivolumab plus standard chemotherapy receives FDA approval for classical Hodgkin lymphoma, expanding immunotherapy's role in blood cancers.
Drug Approval
May 27, 2026 0
Metabolic Health
FDA Fast-Tracks New Weight Loss Drug Foundayo Under Priority Program
Orforglipron approved 294 days ahead of schedule for obesity treatment, marking first drug under new priority voucher system.
Drug Approval
Apr 16, 2026 0
Brain Health
FDA Approves First Drug for Hunter Syndrome Brain Complications in Children
Avlayah becomes the first treatment targeting neurologic symptoms of rare genetic disorder affecting 500 Americans.
Drug Approval
Apr 15, 2026 0
Metabolic Health
FDA Approves Two New Weight Loss Drugs in Record Two-Week Span
Foundayo and Zepbound receive rapid FDA approval for chronic weight management in adults with obesity or weight-related conditions.
Drug Approval
Apr 5, 2026 0
Page 1 of 2Next